Glenmark gets USFDA approval for cholesterol drug
New Delhi: Glenmark Pharmaceuticals has received final approval from the US health regulator for Colesevelam Hydrochloride for oral suspension, used to lower cholesterol levels in the blood.
The approval has been granted by the United States Food and Drug Administration (USFDA) in the strengths of 1.875 grams/packet and 3.75 grams/packet, the company said in a BSE filing today.
The approved product is a generic version of Daiichi Sankyo Inc's Welchol.
Quoting IQVIA sales data for the 12-month period ended May 2018, the company said Welchol achieved annual sales of around USD 73 million.
The company's current portfolio consists of 138 products authorized for distribution in the US market, and 62 Abbreviated New Drug Applications (ANDAs) are pending approval with the USFDA, it added.
abbreviated new drug applicationsapprovalcholesterol drugcholesterol lowering drugcolesevelam hydrochlorideDaiichi Sankyogeneric versionGlenmarkGlenmark PharmaGlenmark Pharmaceuticalslower cholesterol levelsOral SuspensionUnited States Food and Drug AdministrationUSFDAWelcholWelchol tablets
Source : PTINext Story
NO DATA FOUND
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd